Exchange: OTC·Updated 04:00 PM EDT

BAYRYBayer AG (ADR)

$15.19
$1.34
(9.64%)
Today
EarningsAug 4
Mkt Cap$59.67B
Vol1.21M
News
all
press releases
NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population
Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.
Zacks
News Placeholder
More News
News Placeholder
BAYRY Stock Surges 17% After Supreme Court Roundup Ruling
Bayer shares jump 17% after a Supreme Court ruling on Roundup litigation that could significantly reduce warning-based claims and litigation costs.
Zacks
News Placeholder
Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?
Bayer (BAYRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Zacks
News Placeholder
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.
Zacks
News Placeholder
Bayer (BAYRY) Upgraded to Buy: What Does It Mean for the Stock?
Bayer (BAYRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study
Novartis reports phase III RemIND success for Rhapsido in chronic inducible urticaria, showing higher response rates and supporting new filings.
Zacks
News Placeholder
Novartis Reports Positive Data for Neuromuscular Disorder Drug
NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.
Zacks
News Placeholder
EMA Begins Review of Bayer's Asundexian Filing for Stroke Prevention
BAYRY's asundexian enters EMA review for stroke prevention after phase III data showed a 26% cut in ischemic stroke without more major bleeding.
Zacks
News Placeholder
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
Zacks
<
1
2
...
>

Advertisement|Remove ads.